• Results for the First Quarter 2018

    Currency neutral sales of own products decreased with 2.7 %. Operating profit (EBIT) ended at MNOK 13.6 (MNOK 16.0). Medistims equipment received an updated recommendation by NICE in UK. Data collection in the REQUEST study…

    Read more
  • Annual Report 2017

    We have further strengthened our position within cardiac bypass surgery, in particular in our most important market USA, where we now have achieved a market penetration of 20% measured as the share of bypass procedures…

    Read more
  • Results for the Fourth Quarter and Preliminary Results for 2017

    Currency neutral sales of own products increased by 31.3 % for the quarter. For 2017, currency neutral growth in sales of own products was 15.7%. EBIT for the quarter ended at MNOK 16.4 (MNOK 9.7),…

    Read more
  • Results for the Third Quarter 2017

    Currency neutral growth of own products is 12.5%. Flow probe sales negatively impacted with MNOK 2.2, however, production of flow probe capacity is improving and backorder is reduced from 500 to 250 probes. Another strong…

    Read more
  • Results for the Second Quarter 2017

    Currency neutral growth of own products was 4.7 % and was negatively impacted by delayed flow probe deliveries amounting to MNOK 5.5. Currency neutral growth of own products was 10.7 % for the 1st half.…

    Read more
  • Results for the Fourth Quarter 2016

    Currency neutral sales of own products decreased with 3 MNOK or 5.7 % due in part to a back order situation on TTFM flow probes. Currency neutral sales of own products increased with 9.5 %…

    Read more
  • Results for the Third Quarter 2016

    Sales in the 3rd quarter ended at MNOK 67.9 (MNOK 61.6), a 10.2 % increase. USA had a strong quarter with an 18.5% growth in sales. In Asia sales increased with 83.6 % while in…

    Read more
  • Results for the First Quarter 2016

    Sales for the quarter ended at MNOK 65.5 which is a 13.1 % sales growth for the quarter. Sales of own products increased with 28.8 % to MNOK 49.1 and US sales up 42.8 %…

    Read more
  • Medistim Delivers Best Quarter Ever

    Medistim delivers its best quarter ever and sales ended at MNOK 66.1 (MNOK 52.2), a growth of 26.6 %. Sales for 2014 ended at MNOK 214.8 (MNOK 191.0), a growth of 12.5 %. The atrong…

    Read more
  • Results for the Third Quarter 2014

    Sales for the quarter ended at MNOK 52.0 (MNOK 44.3), a growth of 17 %. Sales as of September ended at MNOK 148.7 (MNOK 138.8), a growth of 7.1 %. • Continued strong growth in…

    Read more